Drug General Information (ID: DDISDQZ6J1)
Drug Name			Sunitinib		Drug Info		Lacosamide		Drug Info
Drug Type		Small molecule				Small molecule
Therapeutic Class		Antineoplastics				Analgesics
Structure

Mechanism of Sunitinib-Lacosamide Interaction (Severity Level: Moderate)
Increased risk of atrioventricular block Click to Show/Hide Mechanism Graph
Drug Name		Sunitinib				Lacosamide
Mechanism		Delay atrioventricular conduction				Delay atrioventricular conduction
Key Mechanism Factor 1
		Factor Name		Atrioventricular block
		Factor Description		Atrioventricular block is a type of cardiac conduction block that occurs when the electrical signal from the atria to the ventricles is impaired. In an Atrioventricular block, this electrical signal is either delayed or completely blocked. When the signal is completely blocked, the ventricles produce their own electrical signal to control the heart rate. The heart rate produced by the ventricles is much slower than that produced by the sinus node.
Mechanism Description		Increased risk of atrioventricular block by the combination of Sunitinib and Lacosamide

Recommended Action
Management		Caution is advised if sunitinib is used concomitantly with other agents that prolong the PR interval, especially in the elderly and patients with known conduction problems (e.g., marked first-degree AV block second-degree or higher AV block sick sinus syndrome without pacemaker) or severe cardiac disease such as myocardial ischemia or heart failure. Patients should be advised to notify their doctor if they experience dizziness, lightheadedness, fainting, or irregular heartbeat.

References
1	Product Information. Sutent (sunitinib). Pfizer U.S. Pharmaceuticals Group, New York, NY.
2	Canadian Pharmacists Association "e-CPS."